Warning: I have nothing encouraging or positive to say in this latest installment of my small-cap biotech column featuring ResTORbio (TORC) — damn, that’s a stupid spelling — Trovagene (TROV), and Atossa Genetics (ATOS). I start in skeptical, glass-half-empty mode before going full-tilt “GET OFF MY LAWN!” You like that best, right?

ResTORbio said last week that the FDA agreed to its proposed design for Phase 3 clinical trials that use a less stringent primary endpoint than the one used by the company in its Phase 2 clinical trial. A less demanding primary endpoint means greater odds of clinical trial success, which in turn, means a higher likelihood that ResTORbio’s drug is approved. Or, so ResTORbio bulls will tell you.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy